More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Hims & Hers Health (NYSE: HIMS) tumbled 5.6% through 12:20 p.m. ET Thursday after Bank of America analysts gave mixed messages on the stock this morning. Raising its price target on the shares to $21, ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

American doctors, who tracked over 37 million people, said the injections put users at higher risk of nonarteritic ischemic ...

The 36-year-old rapper-singer-flautist successfully lowered her body mass index (BMI) by 10.5 and lost 16% of her body fat on ...

Hims & Hers Health, Inc. shares surged 17.5% on Wednesday, marking their best performance in a week and hitting fresh highs ...

Ozempic may also help people drink less alcohol. Primary care doctors are concerned about patients accessing GLP-1s through ...

As India awaits the launch of obesity drug, Mounjaro, the debate on weight loss drugs and body image continues ...

The Super Bowl aired a Hims & Hers commercial that is receiving backlash for its non-FDA approved weight loss drug. This drug ...

Canaccord raised the firm’s price target on Hims & Hers to $68 from $38 and keeps a Buy rating on the shares. Thefirm noted shares are up ...

Online pharmacies must now conduct in-person consultations before dispensing weight-loss medications, ensuring safe and appropriate use of high-risk drugs.